[{"id":"74103f95-a32d-408a-8b21-f7f3138423b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04156178","created_at":"2021-01-18T20:16:38.664Z","updated_at":"2024-07-02T16:36:53.862Z","phase":"Phase 1","brief_title":"CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies","source_id_and_acronym":"NCT04156178","lead_sponsor":"iCell Gene Therapeutics","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression • CD19 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20-CD19 cCAR T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 12","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 09/30/2020","study_completion_date":" 09/30/2020","last_update_posted":"2019-11-12"}]